Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Study of a Study Medicine for Recurrent Malignant Lymphoma

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Recruiting
25 years - 100 years
Male
Phase N/A
3 Locations

Brief description of study

The primary objective is to assess the safety and tolerability of JS-001 in subjects with recurrent malignant lymphoma, and to evaluate its preliminary efficacy.

The secondary objectives are to: 1) characterize the single-dose and multi-dose pharmacokinetic (PK) profile of JS-001, 2) characterize the immunogenicity of JS-001; 3) assess the dose-efficacy relationship of JS-001 single agent, and 4) preliminarily evaluate biomarkers associated with the efficacy of JS-001.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma
  • Age: 25 years - 100 years
  • Gender: Male

Inclusion Criteria:
  •  
Exclusion Criteria:
  •  
 

The purpose of this research study is to learn about the safety and tolerability (how well people can handle side effects) of a study medicine in people with recurrent malignant lymphoma (lymphoma that has come back). The study will also look at the study medicine’s early effects on the lymphoma.

Participants will receive the study medicine. The study will also measure how the medicine moves through the body after 1 dose and after multiple doses (pharmacokinetics). It will check whether the body makes an immune response against the medicine (immunogenicity). The study will also look at how the dose relates to the medicine’s effects and will explore biological markers (biomarkers) that may be linked to how the medicine works.

Updated on 19 Aug 2026. Study ID: IRB-90879

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team